)
Visual21 Nov 2025
Data center suppliers
Xencor (XNCR) investor relations material
Xencor TD Cowen Immunology and Inflammation Summit summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen Immunology and Inflammation Summit summary12 Nov, 2025
Strategic focus and pipeline overview
Emphasis on delivering new medicines in oncology and autoimmune diseases using XmAb protein design tools.
Oncology portfolio focused on T-cell engagers; expansion into autoimmune with TL1A axis and B-cell depleters.
Recent progress includes phase I completion for XmAb942 (TL1A antibody) and initiation of phase II-B in ulcerative colitis.
Oncology highlights: ENPP3xCD3 T-cell engager (XmAb819) showed 25% response in heavily pretreated RCC; CLDN6 CD3 for ovarian/germ cell tumors progressing in dose escalation.
Multiple phase III studies underway or planned with partners, including Amgen and Astellas, in prostate and gastric cancers.
Autoimmune pipeline and differentiation
XmAb942 leverages half-life extension technology for high potency and infrequent dosing (every 12 weeks), aiming for best-in-class anti-TL1A therapy.
Phase II-B study for XmAb942 is a rigorous, global, three-dose vs. placebo design to efficiently identify phase III dose.
Bispecific TL1A/IL-23 (412) designed for potent, convenient, single-injection therapy, targeting dual inflammatory pathways in IBD.
Both 942 and 412 expected to address different patient populations and expand beyond IBD, with 942 offering broader flexibility.
B-cell depleter programs and clinical strategy
Plamotamab (CD20xCD3) in RA leverages oncology experience for dosing and safety, aiming for easy, well-tolerated regimens.
Success metrics include deep B-cell depletion, manageable administration, and early efficacy signals.
XmAb657 designed for potent, multi-month B-cell depletion with simple administration; clinical studies underway.
Indication selection for CD19 and CD20 programs guided by unmet need, safety, and efficacy considerations, with rapid assessment planned.
XmAb 819's market impact in RCC
XmAb 942/412 competitive market strategy
CD19 vs CD20 B-cell depleter strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Xencor earnings date
Piper Sandler 37th Annual Healthcare Conference2 Dec, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Xencor Inc. is a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies and cytokine therapies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb technology to create antibody-based therapies that enhance immune responses or modulate immune activity. Xencor's pipeline includes candidates designed to target specific proteins involved in disease processes, aiming to provide more effective and durable treatments. The company is involved in both internal research and collaborations with other biopharma companies to advance its therapies through clinical trials. The company is headquartered in Monrovia, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage